| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  Oxford Drug Design A drug-discovery company focused on oncology. Follow us on Twitter @OxDrugDes Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates … 100 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology A.I. - Machine Learning A.I. | 5 | 10 |
 | Immitra Bio GmbH We turn blood stem cells into living drug factories At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable. 216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 3 |
 | Ksilink Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle 239 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology | 4 | 18 |
 |  DeepLife AI for digital twin of cells DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, … 87 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning SaaS | 30 | 30 |
 | Mosaic TX Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active … 158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 26 |
 |  Abtech Therapeutics Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible. 258 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 2 |
 | Minos Biosciences What You See Is What You Seq - Revolutionary cell analysis solution for fundamental, translational & pharma/biotech R&D Minos Biosciences is on the path to bridge molecular and cell biology in a manner never achieved before that will, in turn, allow scientists to uncover the full picture of cell diversity and dynamics. By combining multi-omics analysis with phenotypic analysis at cell resolution and at high throughput, Minos’ solution provides a new paradigm in cell analysis that will open up new frontiers in life science research, precision medicine and diagnostics. 64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 14 | 15 |
 | Nuage Therapeutics We develop new selective and potent drugs for intrinsically disordered targets. Nuage Therapeutics is a biotech company focused on developing small molecule inhibitors of oncogenic transcription factors. The company has a particular focus on drugging cell lineage-specific transcription factors that are known cancer dependency genes. Built on a deep understanding of transcriptional regulation and the biophysics of intrinsically-disordered proteins (IDPs), Nuage has developed technologies that enable the ‘capture’ of IDPs in higher-order, self-assembled states that present binding pockets that render these proteins amenable to small molecule drug discovery. This represents a game-changing advance that has led to the identification of … 2 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 25 |
 | Curve Therapeutics Revolutionary intracellular screening platform enables a new generation of first-in-class drugs. Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged. Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes. We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets. 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 36 |
 | SynHelix (now Quantoom Biosciences, a Univercells Company) Large-scale DNA synthesis technology that harnesses natural enzymes. Since January 2022, SynHelix is part of Quantoom Biosciences. Please go to the Quantoom Biosciences Linkedin page or www.quantoom.com for more information. Molecular biology, synthetic biology, biotechnology, Biochemistry, Surface chemistry, lifesciences, computational biology, gene synthesis, gene therapy, cell therapy, bioeconomy, enzymology, Biocatalysis, Bioengineering, Enzyme engineering, Biotherapeutics, Protein engineering, Recombinant proteins, and nanotechnology 90 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 3 |
 | METAFORA biosystems AI-Powered Cytometry & Cell Metabolism Profiling At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health. biomarkeurs, cell metabolism, flow cytometry, data analysis, biotechnology, IVD tests, diagnostics, diagnostic tests, cell biology, neurometabolic diseases, metabolic diseases, oncology, multiple myeloma, and research 78 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 23 | 36 |
 | NEBULA Transforming Drug Target Discovery with Physics-Based dataset-free genAI Partnerships At NEBULA, we revolutionize drug discovery by providing a comprehensive, physics-based dataset-free genAI solution for mapping the full range of therapeutic target conformations. Unlike traditional drug development focused on small molecule screening, our innovative approach delves deep into the dynamic nature of macromolecular targets—proteins, mRNA, antigens—unveiling their multitude of physiological conformations. Our dataset-free technology integrates generative genAI with molecular dynamics, rooted in physical principles, to generate an exhaustive profile of potential target structures without relying on pre-existing data. By enhancing the understanding of drug targets, we empower pharmaceutical and biotech companies … 50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. Generative A.I. | 10 | 5 |
 | Selexis SA Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, … 138 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 27 |
 | ASTRA Therapeutics Precision Drugs against Eucaryotic Pathogens ASTRA Therapeutics is a Drug Discovery company with a mission to design and develop novel, precision engineered drugs against a whole range of Eukaryotic Pathogens. 505 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 4 |
 | Invitris A startup using Synthetic Biology to innovate the way we develop entirely novel classes of protein-based drugs. Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, such as the next generation of antibiotics. 124 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 21 |
 | One Biosciences Focused on generating precision medicines by leveraging the power of single-cell technologies One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Institut Curie and Home Biosciences. 66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 22 |
 | Kezar Life Sciences Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be … 153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 60 |
 | Senti Biosciences Outsmarting complex diseases with more intelligent medicines Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell … 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 68 |
 | Cytochroma Accelerating global drug development Cytochroma predict how drugs will react in a global population in health or disease. Our unique, ethnically diverse library of iPSC and automated cell culture generates robust, reliable, mature hepatocytes for toxicity testing. We are supporting life science companies, de-risking safe compounds prior to clinical testing, making new drug development faster, safer and more efficient. toxicity testing, liver specialists, hepatocyte testing, disease models, high throughput, high content screening, iPSC, automated manufacture, machine learning, artificial intelligence, predictive testing, and pre clinical testing 132 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 2 | 4 |
 | AnyGenes® Since more than 10 years, AnyGenes® scientists develop and produce innovative high throughput screening products for signaling pathway analysis. These kits and reagents allow high throughput transcriptomic analysis of a large collection of signaling pathways in many species, biomarkers identification and validation, as well as validation of microarrays results. AnyGenes®, with its innovative & cost effective technologies, products and its proprietary molecular platform, helps scientists to accelerate their projects, publications, and biotech companies for drug development and biomarkers validation. Located in Paris, within Tenon Hospital in the 20th arrondissement, AnyGenes® constitutes a key player in the Biotechnology field. Supported by … 20 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 5 |
 | kyron.bio Next generation bioproduction platform Kyron.bio is revolutionising the way we make our therapeutic drugs. Our novel engineering strategy allows us to precisely control the glycosylation pattern on the surface of a biologic in order to develop the next generation of medicines. This unique approach enables us to sculpt biologics based on the sugars that are attached to the surface, helping to make therapeutics safer and more effective. Our work at Kyron.Bio is opening up a new era of biologics engineering – one with the power to create positive health outcomes for patients whose needs are currently unserved by the pharmaceutical … 64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 8 |
 | Depixus Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies. Single molecule analysis, RNA Drug Discovery, Protein-protein Interaction Analysis, Biophysics, Drug Discovery, Compound Screening, biomolecular interactions, and interactomics 155 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 57 |
 | AUM Biosciences Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules 549 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 18 |
 | Ikena Oncology Patient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which … 125 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 23 |
 | MiNA Therapeutics Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery 211 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 33 |
 | Causeway Sensors Limited Causeway Sensors uses nanotechnology to provide better candidate selection during drug development. The company spun-out after years of high-impact research at Queen's University Belfast. Our unique nanochip platform brings real-time, label-free kinetic analysis to areas of biotherapeutic production where such data cannot currently be collected. More data at critical points of production helps pharma companies ensure that only the best drug candidates progress to clinical trials. The platform can be incorporated into a multitude of form factors, ranging from a high-throughput screening instrument to an in-line cell culture monitoring tool. Biosensing, Protein - Protein Interactions, Binding Kinetics, Biotechnology, Biotherapeutics, Antibody … 90 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 3 | 12 |
 | TRON-Mainz Science in Translation - We put inspiration into practice, finding viable solutions to complex challenges. Our mission is to turn scientific breakthroughs into progress for patients. TRON is a non-profit research institute that pursues new diagnostics and drugs for the treatment of cancer and other diseases with a high medical need. We aim to bridge the gap between fundamental science at universities and market-oriented research in the pharmaceutical industry. We turn innovative scientific concepts into treatments ready for clinical testing, thereby accelerating the translation of discoveries into new diagnostics and therapies for patients. We focus our transdisciplinary competencies in genomics … 122 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 188 |
 | Lexicon Pharmaceuticals, Inc. At Lexicon, We Pioneer Medicines that Transform Patients' Lives Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies … 60 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 321 |
 | Genomic Expression Inc The RNA Platform - by analyzing RNA we can detect disease, monitor health and design the Next Generation Cures Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression’s OneRNATM test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA’s to approved therapies and clinical trials. Genomics, information, personalized medicine, personalized diagnostics, Sequencing, prognostics, bioinformatics, sample preparation, Next Generation Sequencing, Biobank, Access to biological samples, target filtering, RNA-seq, RNA sequencing, and RNASeq of FFPE samples 103 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 10 |
 | Pencil Biosciences Limited Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing 294 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 16 |
 | Ranomics Ranomics offers innovative solutions for protein engineering, drug discovery, genomics research and synthetic biology Ranomics offers high throughput solutions for protein engineering, drug discovery, genomics research and synthetic biology. Using our VariantFind and VERG genomics platforms, Ranomics offers partners the a scalable solution to engineer and screen genetic variants in a wide range of model organisms. Our industry leading DNA Variant libraries and high-throughput cell assays help researchers to hit their research objectives faster and with better results than traditional methods. Over the years, we have worked with top biotech and pharma companies in the US and worldwide. Our partners … 183 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 7 |
 | Biosortia, Inc. Unlocking the Hidden Chemistry of Microbiomes for Next-Generation Therapeutics with ISMM • Expanding Customer Pipelines Biosortia Pharmaceuticals is pioneering a revolutionary approach in drug discovery through its Industrial Scale Microbiome Mining (ISMM) technology. By accessing the vast, untapped chemical diversity found within natural microbiomes, We unlock a hidden world of small molecules that play crucial roles in cellular signaling and disease processes. These small molecules, often referred to as the "drug-like dark matter" of cellular biology, have been largely inaccessible until now. Our technology allows for the large-scale harvesting and exploration of these compounds, providing an unprecedented opportunity to discover … 64 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Data Analytics Synthetic Biology Generative A.I. A.I. - Machine Learning | 1 | 10 |
 | Kernal Biologics KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space. synthetic biology, RNA design, immunotherapy, covid-19, cancer, and mRNA therapy 105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 10 | 15 |
 | JURA Bio, Inc. Building the future of cell-based therapies. CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive. Cell-based Therapies and Machine Learning 115 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology SaaS A.I. Generative A.I. | 0 | 15 |
 | Calico Biosystems Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy 542 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 1 |
 | Foghorn Therapeutics Inc. Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system. 64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 128 |
 | Elixirgen Scientific Transform how you model human biology. Elixirgen Scientific is a global leader in regenerative medicine and biotechnology, headquartered in the Science + Technology Park at the Johns Hopkins Medical Campus in Baltimore, MD. Our mission is to advance science and medicine with fast, functional, and scalable induced pluripotent stem cell (iPSC) differentiation products and services. Our state-of-the-art, transcription-factor-based technology allows you to overcome the high cost and inefficiencies associated with lengthy cell differentiation periods. We empower research institutions, pharmaceutical organizations, and biomedical enterprises worldwide, even those with no previous iPSC experience, by increasing access to relevant cells for modeling human … 74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 21 |
 |  Circularis Biotechnologies Using circular RNA to control any gene, in any species, in any cell type. "Acquired by Ginkgo Bioworks in 2022" Control of any Gene in any Species or Cell Type Circularis has used the power of circular RNA to develop a novel method to study and regulate gene expression. This technology has enabled increased bio-therapeutic production, improved targeting of gene therapy, and optimized expression in poorly studied organisms. The elegant design and high throughput nature of this technology enables breakthrough solutions without prior knowledge of the regulatory elements or coding sequence. Gene Expression, Bioprocessing, Molecular Biology, Protein Expression, Drug Discovery, … Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 2 |
 | Formation Bio Bringing new treatments to patients faster and more efficiently. Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program. 174 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 171 |
 | Kano Therapeutics Complete genes for complete cures Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them. Biotechnology, DNA therapeutics, Gene therapy, CRISPR, and Biological engineering 108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 16 |
 | Delta4ai Delta4 is a Vienna-based biotech startup driving the forefront of digital drug discovery and development. Delta4 is driving the forefront of digital drug discovery and development. We leverage a proprietary computational analytics platform "Hyper-C", combining straightforward biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering the most efficient matching of clinical indications and compound/drug effects. drug repositioning, drug discovery, compounds, orphan diseases, indication expansion, AI, and omics 62 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology | 4 | 14 |
 | InterAx Biotech Advanced integration of biological systems, math models and artificial intelligence The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and … 110 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 4 | 15 |
 | QUANTRO Therapeutics GmbH Discovery and development of novel therapeutics targeting transcription factors in cancer and other diseases QUANTRO Therapeutics (“QUANTRO”) is a research-based entity that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programs in cancer and other diseases. QUANTRO will assemble a highly innovative drug-discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates interfering with transcriptional regulators. The first focus will be on cancer-associated transcription factors, which so far have been unamenable to pharmacologic intervention. QUANTRO was founded as a spin-off of the Institute of Molecular Biotechnology (“IMBA”) and the Research Institute … 56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 16 |
 | CN Bio Generate human-specific efficacy and safety data with PhysioMimix® Single- and Multi-organ microphysiological systems. CN Bio is a leading organ-on-a-chip (OOC) company that enables researchers to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® suite of microphysiological systems, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Intestine/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment and function of … 55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 61 |
 | CellSine Discover your favorite frequencies to boost your drug discovery business CellSine provides devices and software that make advanced electrochemical impedance spectroscopy easily accessible to any microbiological researcher. It delivers a platform tool for a that enables a wide variety of biochemical studies. Biotechnology, Cell culture monitoring, Proteïn - Proteïn interactions, Suspension cultures, Receptor signaling, Biofilm maturation, and T lymphocyte activation 206 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 4 |
 | Platinum Discovery Multiomics research for precision medicines Platinum Discovery offers a cutting-edge Tumour-to-Target Platform, specialising in cancer vaccine development through the identification of tumour-specific neoantigens. We provide a comprehensive, end-to-end drug discovery pipeline, supporting clinical trial research and translational science for patient samples. Our multidisciplinary team brings together expertise in biology, clinical sciences, multi-omics technologies, bioinformatics, and computational sciences, enabling a deep understanding of the biological processes critical to drug development. We excel at integrating diverse scientific domains to deliver holistic, innovative solutions. With extensive experience in designing and managing complex research programmes, we assemble tailored teams of experts, drawing on our … 111 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 4 |
 | OPPILOTECH LTD Navigating Biology, Discovering Drugs Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. We use the models to simulate biological processes in order to identify viable drug targets and discover new biology. The company is building a pipeline of first-in-class drug discovery programmes based on the identified targets. 82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. A.I. - Machine Learning | 1 | 11 |
 | Relation Discovering the relationships at the heart of biology to cure disease. We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select … 77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 14 | 86 |
 | InFocus Therapeutics Innovating a New Class of Medicines to Drug the Undruggable InFocus is a discovery-stage biotechnology company dedicated to true innovation for novel therapeutic modalities. We are integrating unique experimental technologies with a state-of-the-art algorithm-driven drug discovery platform, to develop next-generation small molecule drugs against undruggable targets at unprecedented scale. 116 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 11 |
 | Cellarity Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas … 281 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology | 4 | 104 |
 | Standard BioTools Providing essential, standardized tools to accelerate breakthroughs in human health Microfluidics | Cytometry | Imaging Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies. Mass Cytometry, Tissue Imaging, NGS Library Prep, Genotyping, Gene Expression, Copy Number Variation, Real-Time PCR, and Single-Cell Genomics 184 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 929 |
 | Keltic Pharma Therapeutics The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic. 106 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 11 |
 | PharmEnable Therapeutics Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, … 110 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 20 |
 | Plasticell Limited Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details. Stem Cell Research, Biotechnology, and High Throughput Stemcell Research 102 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 11 |
 | NewBiologix Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines 286 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 22 |